Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

By M. Sabatine, R. Giugliano, S. Wiviott, F. Raal, D. Blom, Jennifer G. Robinson, Christie M. Ballantyne, R. Somaratne, J. Legg, S. Wasserman and 3 more. New England Journal of Medicine, 2015

1,138 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/3a2aa2d61647c779adc7c8fa42c75fb373940128

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

I. Graham

In Endocrinology, Diabetes and Metabolism

In Surgery

Citations in the corpus

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “When added to maximal statin therapy, these once- or twice-monthly injectable agents reduce LDL-C by approximately 50%, raise HDL-C, and have favorable effects on other lipids (191-197).”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, result): “); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.(115,116) A recent meta-analysis confirmed these findings.”
2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. (2016, result): “The observation of a large and concordant relative reduction (approximately 50%) in clinical outcomes, in their LDL-C efficacy studies (Open-Label Study of Long-Term Evaluation Against LDL-C [OSLER] and Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hyperch”
The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. (2015, background): “PCSK9 inhibitors alirocumab and evolocumab have now been approved by the FDA for this purpose, based on LDL lowering and short-term studies suggesting a decrease in composite cardiovascular end points.(149,150) Definitive hard outcomes data are not yet available.”